Jan, 11 2018 11:46 JST

Source: Eisai

Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China


TOKYO, Jan, 11 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.

Aiming to further expand its contribution to patients in China, Eisai has been working to establish a new Suzhou plant on a new industrial site more than five times larger than the current Suzhou Plant (OSD production facility) to further strengthen the stable supply chain as well as improve production efficiency.

ECI established a parenteral facility in November 2014, where it manufactures the injection formulation of Methycobal. The newly completed OSD production facility stands three floors aboveground and contains floor space of approximately 20,240 m2, and its production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) is approximately double that of the current Suzhou Plant. Operations are expected to commence in the second half of fiscal 2018, and the new OSD facility will handle the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. The current plant will be closed after operations fully commence at the new Suzhou Plant's OSD production facility.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. Through the completion of the OSD production facility at the new Suzhou Plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Eisai Co., Ltd.
Public Relations Department
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
December 06 2018 09:24 JST
 
Eisai: MOVICOL Launched in Japan
November 29 2018 13:48 JST
 
Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
November 28 2018 10:55 JST
 
Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
November 27 2018 17:02 JST
 
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
November 23 2018 07:14 JST
 
Eisai Receives "IR Grand Prix Award"
November 14 2018 12:30 JST
 
Eisai Launches Lenvima (Lenvatinib) in China
November 12 2018 11:51 JST
 
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
November 09 2018 08:08 JST
 
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
November 08 2018 14:38 JST
 
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
November 08 2018 08:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>